Dotmatics Cloud Hosted Platform Enables AstraZeneca Neuroscience Drug Discovery Collaborations

24 Jul 2013
Kerry Parker
CEO

Industry news

Dotmatics has announced that the AstraZeneca Neuroscience Innovative Medicines Unit (iMed) has selected its Cloud based informatics platform as their research data management solution. The Dotmatics platform provides a single point of access to all data and functions across multidisciplinary groups. The platform includes compound registration and tracking, biological screening, DMPK analysis, as well as a fully integrated chemistry and biology ELN and project management. This flexibility enables AstraZeneca scientists, collaborators and partners to instantly interact with the same data regardless of location and timezone, fulfilling the promise of real time research.

The AstraZeneca Neuroscience iMed’s strategy focuses on accessing cutting-edge science and world-class capabilities through partnership and collaboration with academia, industry and contract research organizations. The iMed manages a portfolio of drug discovery and development projects exclusively with external partners. Since it was created just over a year ago, the iMed has implemented innovative technologies that enable it to work seamlessly with external partners.

“We are excited to see the Dotmatics platform enabling and enriching the collaborative research capabilities of AstraZeneca’s Neuroscience iMed,” commented Dr. Stephen Gallagher, CEO of Dotmatics. “Today’s industry demands modern informatics solutions to accommodate the different ways in which people work, be it internally or externally, with CROs or partners. Our platform delivers this and, at the same time, eliminates the IT burden associated with global informatics infrastructure.”

“We were seeking an enterprise data management solution that would be comprehensive and get us up and running from day one. Dotmatics platform gives us the ability to collaborate and share data easily, securely and in real time,” said Dr. Mark Duggan, Vice President of Neuroscience iMed.

AstraZeneca Neuroscience is leading the way with its use of the Dotmatics platform for scientific data management which is a model for global externalized collaboration. The flexible nature of the Dotmatics platform delivers on the promise that scientists can easily and securely access their data at any time, from any location.

Links

Tags

High-Throughput ScreeningHigh-throughput screening (HTS) is an automated drug discovery technique for identification of active compounds against a compound library. Use HTS readers and integrated assay preparation / analysis workstations to screen your compounds. Identify active compounds against various HTS libraries, including membranes, proteins and peptides and HTS cell lines. Find the best high-throughput screening products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.ADME-ToxicologyADME-toxicology (ADME-Tox) studies are used in pharmacology and pharmacokinetics to assess the activity/toxicity of drugs <i>in vivo</i> or <i>in vitro</i>. Find bioassays for absorption, distribution, metabolism, and excretion of drug molecules including cytotoxicity, transporter/permeability, metabolism and activity assays as well as hepatocytes and cell lines for ADME. Find the best ADME-toxicology products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.ScreeningUsing robotics, data processing and control software, liquid handling devices and sensitive detectors, screening allows a researcher to quickly conduct millions of chemical, genetic or pharmacological tests.NeuroscienceNeuroscience research investigates the neurological mechanisms underlying behavior, neurodegenerative diseases, and other brain conditions. Learn about the innovative technologies for bioimaging, electrophysiology, cell culture, chromatography and other techniques used in this field.Compound ScreeningCompound screening is a method used to discover specific compounds that could be promising candidates for pharmaceutical use. This potential is identified when compounds interact with the target protein during screening and could therefore be carried forward in the drug development process.